Literature DB >> 23489978

(1)H magnetic resonance spectroscopy in the diagnosis of paediatric low grade brain tumours.

E Orphanidou-Vlachou1, D Auer, M A Brundler, N P Davies, T Jaspan, L MacPherson, K Natarajan, Y Sun, T N Arvanitis, R G Grundy, A C Peet.   

Abstract

INTRODUCTION: Low grade gliomas are the commonest brain tumours in children but present in a myriad of ways, each with its own treatment challenges. Conventional MRI scans play an important role in their management but have limited ability to identify likely clinical behaviour. The aim of this study is to investigate (1)H magnetic resonance spectroscopy (MRS) as a method for detecting differences between the various low grade gliomas and related tumours in children. PATIENTS AND METHODS: Short echo time single voxel (1)H MRS at 1.5 or 3.0 T was performed prior to treatment on children with low grade brain tumours at two centres and five MR scanners, 69 cases had data which passed quality control. MRS data was processed using LCModel to give mean spectra and metabolite concentrations which were compared using T-tests, ANOVA, Receiver Operator Characteristic curves and logistic regression in SPSS.
RESULTS: Significant differences were found in concentrations of key metabolites between glioneuronal and glial tumours (T-test p<0.05) and between most of the individual histological subtypes of low grade gliomas. The discriminatory metabolites identified, such as choline and myoinositol, are known tumour biomarkers. In the set of pilocytic astrocytomas and unbiopsied optic pathway gliomas, significant differences (p<0.05, ANOVA) were found in metabolite profiles of tumours depending on location and patient neurofibromatosis type 1 status. Logistic regression analyses yielded equations which could be used to assess the probability of a tumour being of a specific type.
CONCLUSIONS: MRS can detect subtle differences between low grade brain tumours in children and should form part of the clinical assessment of these tumours.
Copyright © 2013. Published by Elsevier Ireland Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23489978     DOI: 10.1016/j.ejrad.2013.01.030

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  9 in total

1.  Differentiation of hemangioblastomas from pilocytic astrocytomas using 3-T magnetic resonance perfusion-weighted imaging and MR spectroscopy.

Authors:  D J She; Z Xing; Z Zeng; X Y Shang; D R Cao
Journal:  Neuroradiology       Date:  2014-12-07       Impact factor: 2.804

2.  Response Assessment in Pediatric Neuro-Oncology: Implementation and Expansion of the RANO Criteria in a Randomized Phase II Trial of Pediatric Patients with Newly Diagnosed High-Grade Gliomas.

Authors:  T Jaspan; P S Morgan; M Warmuth-Metz; E Sanchez Aliaga; D Warren; R Calmon; J Grill; D Hargrave; J Garcia; G Zahlmann
Journal:  AJNR Am J Neuroradiol       Date:  2016-04-28       Impact factor: 3.825

3.  Magnetic Resonance Spectroscopy and Single-Photon Emission Computed Tomography in the Evaluation of Cerebral Tumors: A Case Report.

Authors:  Ioannis Siasios; Varvara Valotassiou; Eftychia Kapsalaki; Ioannis Tsougos; Panagiotis Georgoulias; Aggeliki Fotiadou; Maria Ioannou; Georgios Koukoulis; Vassilios Dimopoulos; Kostas Fountas
Journal:  J Clin Med Res       Date:  2016-11-24

4.  Diagnostic accuracy and added value of qualitative radiological review of 1H-magnetic resonance spectroscopy in evaluation of childhood brain tumors.

Authors:  Karen A Manias; Simrandip K Gill; Lesley MacPherson; Adam Oates; Benjamin Pinkey; Paul Davies; Niloufar Zarinabad; Nigel P Davies; Ben Babourina-Brooks; Martin Wilson; Andrew C Peet
Journal:  Neurooncol Pract       Date:  2019-05-09

5.  Diagnosing relapse in children's brain tumors using metabolite profiles.

Authors:  Simrandip K Gill; Martin Wilson; Nigel P Davies; Lesley MacPherson; Martin English; Theodoros N Arvanitis; Andrew C Peet
Journal:  Neuro Oncol       Date:  2013-12-04       Impact factor: 12.300

6.  Metabolite profiling in retinoblastoma identifies novel clinicopathological subgroups.

Authors:  Sarah Kohe; Marie-Anne Brundler; Helen Jenkinson; Manoj Parulekar; Martin Wilson; Andrew C Peet; Carmel M McConville
Journal:  Br J Cancer       Date:  2015-09-08       Impact factor: 7.640

7.  Evaluation of the added value of 1H-magnetic resonance spectroscopy for the diagnosis of pediatric brain lesions in clinical practice.

Authors:  Karen Manias; Simrandip K Gill; Niloufar Zarinabad; Paul Davies; Martin English; Daniel Ford; Lesley MacPherson; Ina Nicklaus-Wollenteit; Adam Oates; Guirish Solanki; Jenny Adamski; Martin Wilson; Andrew C Peet
Journal:  Neurooncol Pract       Date:  2017-05-13

8.  ACRIN 6684: Multicenter, phase II assessment of tumor hypoxia in newly diagnosed glioblastoma using magnetic resonance spectroscopy.

Authors:  Eva-Maria Ratai; Zheng Zhang; James Fink; Mark Muzi; Lucy Hanna; Erin Greco; Todd Richards; Daniel Kim; Ovidiu C Andronesi; Akiva Mintz; Lale Kostakoglu; Melissa Prah; Benjamin Ellingson; Kathleen Schmainda; Gregory Sorensen; Daniel Barboriak; David Mankoff; Elizabeth R Gerstner
Journal:  PLoS One       Date:  2018-06-14       Impact factor: 3.752

Review 9.  Hyperpolarized 13C MRI: A novel approach for probing cerebral metabolism in health and neurological disease.

Authors:  James T Grist; Jack J Miller; Fulvio Zaccagna; Mary A McLean; Frank Riemer; Tomasz Matys; Damian J Tyler; Christoffer Laustsen; Alasdair J Coles; Ferdia A Gallagher
Journal:  J Cereb Blood Flow Metab       Date:  2020-03-10       Impact factor: 6.200

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.